{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T11:44:27Z","timestamp":1772019867820,"version":"3.50.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ejps.2019.02.017","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T11:47:44Z","timestamp":1550231264000},"page":"195-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The nested enzyme-within-enterocyte (NEWE) turnover model for predicting dynamic drug and disease effects on the gut wall"],"prefix":"10.1016","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8218-4306","authenticated-orcid":false,"given":"Adam S.","family":"Darwich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard J.","family":"Burt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin","family":"Rostami-Hodjegan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.ejps.2019.02.017_bb0005","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0169-409X(01)00179-X","article-title":"Predicting the impact of physiological and biochemical processes on oral drug bioavailability","volume":"50","author":"Agoram","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2019.02.017_bb0010","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/BF01296064","article-title":"Superior mesenteric artery blood flow in celiac disease","volume":"38","author":"Alvarez","year":"1993","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejps.2019.02.017_bb0015","first-page":"313","article-title":"Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis","volume":"17","author":"Angelis-Stoforidis","year":"1999","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.ejps.2019.02.017_bb0020","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3389\/fphys.2012.00462","article-title":"Modeling drug- and chemical-induced hepatotoxicity with systems biology approaches","volume":"3","author":"Bhattacharya","year":"2012","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejps.2019.02.017_bb0025","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5455\/msm.2012.24.242-247","article-title":"Early and correct diagnosis of celiac disease in the prevention of growth disorders and child development","volume":"24","author":"Brigic","year":"2012","journal-title":"Mater. Soc."},{"key":"10.1016\/j.ejps.2019.02.017_bb0030","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/074823379701300401","article-title":"Physiological parameter values for physiologically based pharmacokinetic models","volume":"13","author":"Brown","year":"1997","journal-title":"Toxicol. Ind. Health"},{"key":"10.1016\/j.ejps.2019.02.017_bb0035","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1124\/dmd.112.046078","article-title":"Progress curve mechanistic modeling approach for assessing time-dependent inhibition of CYP3A4","volume":"40","author":"Burt","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2019.02.017_bb0040","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1055\/s-0029-1185534","article-title":"Toxicological and pharmacokinetic evaluation of concomitant intake of grapefruit juice and simvastatin in rats after repeated treatment over 28\u202fdays","volume":"75","author":"Butterweck","year":"2009","journal-title":"Planta Med."},{"key":"10.1016\/j.ejps.2019.02.017_bb0045","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2147\/IJN.S94370","article-title":"Toward a general physiologically-based pharmacokinetic model for intravenously injected nanoparticles","volume":"11","author":"Carlander","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejps.2019.02.017_bb0050","series-title":"Simcyp Simulator","author":"Certara","year":"2018"},{"key":"10.1016\/j.ejps.2019.02.017_bb0055","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11095-013-1161-x","article-title":"The importance of villous physiology and morphology in mechanistic physiologically-based pharmacokinetic models","volume":"31","author":"Chen","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.02.017_bb0060","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2174\/138920010794328913","article-title":"Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the \"advanced dissolution, absorption, metabolism (ADAM)\" model","volume":"11","author":"Darwich","year":"2010","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejps.2019.02.017_bb0065","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1124\/dmd.114.058404","article-title":"Meta-analysis of the turnover of intestinal epithelia in preclinical animal species and humans","volume":"42","author":"Darwich","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2019.02.017_bb0070","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1002\/jps.20975","article-title":"Grapefruit juice-drug interactions: grapefruit juice and its components inhibit p-glycoprotein (ABCB1) mediated transport of talinolol in caco-2 cells","volume":"96","author":"De Castro","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.02.017_bb0075","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1023\/A:1011907920641","article-title":"Modeling of pharmacokinetic\/pharmacodynamic (PK\/PD) relationships: concepts and perspectives","volume":"16","author":"Derendorf","year":"1999","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.02.017_bb0080","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1046\/j.1365-2036.2003.01784.x","article-title":"Oral and intestinal mucositis - causes and possible treatments","volume":"18","author":"Duncan","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.02.017_bb0085","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.addr.2011.12.009","article-title":"Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers","volume":"64","author":"Ensign","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2019.02.017_bb0090","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1124\/dmd.108.026252","article-title":"Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction","volume":"37","author":"Fahmi","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2019.02.017_bb0095","first-page":"163","article-title":"Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections","volume":"6","author":"Falci","year":"2013","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.ejps.2019.02.017_bb0100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0009-9120(91)90084-R","article-title":"Pharmacology and pharmacokinetics of cyclosporine","volume":"24","author":"Freeman","year":"1991","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ejps.2019.02.017_bb0105","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1517\/17425255.4.7.909","article-title":"Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions","volume":"4","author":"Galetin","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejps.2019.02.017_bb0110","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2174\/138920008786049276","article-title":"Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations","volume":"9","author":"Gertz","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejps.2019.02.017_bb0115","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1124\/dmd.110.032649","article-title":"Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data","volume":"38","author":"Gertz","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2019.02.017_bb0120","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1124\/dmd.111.039248","article-title":"Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction","volume":"39","author":"Gertz","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2019.02.017_bb0125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2017.01.014","article-title":"BCS class IV drugs: highly notorious candidates for formulation development","volume":"248","author":"Ghadi","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2019.02.017_bb0130","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.2174\/138920111798808211","article-title":"The effect of critical illness on drug distribution","volume":"12","author":"Gonzalez","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ejps.2019.02.017_bb0135","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1128\/CMR.00092-12","article-title":"Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents","volume":"26","author":"Gonzalez","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejps.2019.02.017_bb0140","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1503\/cmaj.113-2109","article-title":"Grapefruit-medication interactions","volume":"185","author":"Greenblatt","year":"2013","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.ejps.2019.02.017_bb0145","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0009-9236(03)00118-8","article-title":"Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice","volume":"74","author":"Greenblatt","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.02.017_bb0150","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/00498250600683197","article-title":"Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability","volume":"36","author":"Howgate","year":"2006","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejps.2019.02.017_bb0155","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s40495-016-0059-9","article-title":"Recent advances in development and application of physiologically-based pharmacokinetic (PBPK) models: a transition from academic curiosity to regulatory acceptance","volume":"2","author":"Jamei","year":"2016","journal-title":"Curr. Pharmacol. Rep."},{"key":"10.1016\/j.ejps.2019.02.017_bb0160","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3109\/03639045.2011.645830","article-title":"Enhanced dissolution rate and oral bioavailability of simvastatin nanocrystal prepared by sonoprecipitation","volume":"38","author":"Jiang","year":"2012","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2019.02.017_bb0165","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1365-2125.2001.01370.x","article-title":"Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis","volume":"51","author":"Johnson","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.02.017_bb0170","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11318160-000000000-00000","article-title":"A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance","volume":"49","author":"Johnson","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2019.02.017_bb0175","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/gut.47.5.632","article-title":"Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans","volume":"47","author":"Keefe","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.ejps.2019.02.017_bb0180","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/0140-6736(91)92302-I","article-title":"First-pass metabolism of cyclosporin by the gut","volume":"338","author":"Kolars","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2019.02.017_bb0185","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1172\/JCI116064","article-title":"Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes","volume":"90","author":"Kolars","year":"1992","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejps.2019.02.017_bb0190","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00101-17","article-title":"Impact of mucositis on absorption and systemic drug exposure of isavuconazole","volume":"61","author":"Kovanda","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2019.02.017_bb0195","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0009-9236(96)90022-3","article-title":"Decreased intestinal CYP3A in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism","volume":"59","author":"Lang","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.02.017_bb0200","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00192360","article-title":"Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects","volume":"49","author":"Lundahl","year":"1995","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.02.017_bb0205","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ejps.2016.10.036","article-title":"IMI - Oral biopharmaceutics tools project - evaluation of bottom-up PBPK prediction success part 2: an introduction to the simulation exercise and overview of results","volume":"96","author":"Margolskee","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.02.017_bb0210","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/ajg.2013.151","article-title":"CYP3A4-catalyzed simvastatin metabolism as a non-invasive marker of small intestinal health in celiac disease","volume":"108","author":"Moron","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejps.2019.02.017_bb0215","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","article-title":"Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions","volume":"35","author":"Obach","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2019.02.017_bb0220","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1208\/s12248-016-9965-3","article-title":"Development of a novel simplified PBPK absorption model to explain the higher relative bioavailability of the OROS(R) formulation of oxybutynin","volume":"18","author":"Olivares-Morales","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2019.02.017_bb0225","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1021\/js9701216","article-title":"What surface of the intestinal epithelium is effectively available to permeating drugs?","volume":"87","author":"Oliver","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.02.017_bb0230","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1124\/dmd.31.12.1507","article-title":"Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette review series)","volume":"31","author":"Pang","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2019.02.017_bb0235","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.1365-2125.2003.01833.x","article-title":"The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6","volume":"56","author":"Prueksaritanont","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.02.017_bb0240","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejps.2011.04.008","article-title":"Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover","volume":"43","author":"Rowland Yeo","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.02.017_bb0245","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/AAC.50.1.286-293.2006","article-title":"Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers","volume":"50","author":"Schmitt-Hoffmann","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2019.02.017_bb0250","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/sj.bmt.1702545","article-title":"Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation","volume":"26","author":"Schultz","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ejps.2019.02.017_bb0255","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.5858\/arpa.2012-0354-OA","article-title":"Mechanism of villus atrophy in celiac disease - role of apoptosis and epithelial regeneration","volume":"137","author":"Shalimar","year":"2013","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.ejps.2019.02.017_bb0260","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0016-5085(97)70123-9","article-title":"Gastrointestinal permeability in celiac disease","volume":"112","author":"Smecuol","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejps.2019.02.017_bb0265","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijpharm.2009.02.002","article-title":"Theoretical investigation of passive intestinal membrane permeability using Monte Carlo method to generate drug-like molecule population","volume":"373","author":"Sugano","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2019.02.017_bb0270","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1067\/mcp.2000.104215","article-title":"Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects","volume":"67","author":"Takanaga","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.02.017_bb0275","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1211\/jpp.61.05.0002","article-title":"Cytochrome P450-mediated metabolism in the human gut wall","volume":"61","author":"Thelen","year":"2009","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2019.02.017_bb0280","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.coisb.2017.06.001","article-title":"Quantitative systems pharmacology and the personalized drug-microbiota-diet axis","volume":"4","author":"Thiele","year":"2017","journal-title":"Curr. Opin. Syst. Biol."},{"key":"10.1016\/j.ejps.2019.02.017_bb0285","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/cpdd.376","article-title":"Two phase 1, open-label, mass balance studies to determine the pharmacokinetics of 14 C-labeled isavuconazonium sulfate in healthy male volunteers","volume":"7","author":"Townsend","year":"2018","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ejps.2019.02.017_bb0290","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/138920007782109733","article-title":"Prediction of intestinal first-pass drug metabolism","volume":"8","author":"Yang","year":"2007","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejps.2019.02.017_bb0295","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2174\/138920008784746382","article-title":"Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions","volume":"9","author":"Yang","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejps.2019.02.017_bb0300","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0378-5173(99)00147-7","article-title":"A compartmental absorption and transit model for estimating oral drug absorption","volume":"186","author":"Yu","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2019.02.017_bb0305","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0378-5173(96)04592-9","article-title":"Compartmental transit and dispersion model analysis of small intestinal transit flow in humans","volume":"140","author":"Yu","year":"1996","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2019.02.017_bb0310","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1124\/dmd.109.026658","article-title":"Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite","volume":"37","author":"Zhang","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2019.02.017_bb0315","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2147\/tcrm.1.1.3.53600","article-title":"Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4","volume":"1","author":"Zhou","year":"2005","journal-title":"Ther. Clin. Risk Manag."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719300703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719300703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T02:15:51Z","timestamp":1551838551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098719300703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":63,"alternative-id":["S0928098719300703"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2019.02.017","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The nested enzyme-within-enterocyte (NEWE) turnover model for predicting dynamic drug and disease effects on the gut wall","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2019.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}